FDA approves Gardasil to prevent anal cancer

May 31, 2010, more than 65 million doses of Gardasil have been distributed worldwide since its approval in 2006, according to the manufacturer, Merck & Co. Inc., Whitehouse Station, NJ The most commonly reported side effects fainting, pain injection site, nausea e. Falls after fainting may sometimes cause serious injuries such as head injuries. This can be avoided by keeping the vaccinated person seated for up to 15 minutes after vaccination. This observation period is recommended to monitor severe allergic reactions that may occur after each vaccination.Gardasil will not prevent the development of precancerous lesions associated with anal HPV infections already present at the time of vaccination. For all indications for use approved by the FDA, Gardasil potential advantage is achieved by those who were vaccinated before being infected with strains of HPV vaccine. lexapro and libido

The Food and Drug Administration approved the Gardasil vaccine for the prevention of precancerous lesions and because of associated human papillomavirus types 6, 11, 16 and 18 for those aged 9 to 26 years zoloft weight loss.

The ability of Gardasil to prevent anal cancer and precancerous lesions associated [anal intraepithelial neoplasia grades 1, 2 and 3] caused by infection anal 16/18 was studied in a randomized controlled trial of men’s’ identified as have sex with men . This population was studied because it has the highest incidence of anal cancer. At the end of the study, Gardasil has shown that 78 per cent effective in preventing HPV 16 – and 18-related AIN paxil litigation. Because anal cancer is the same disease in men and women, the efficacy data was used to support the indication for women

Gardasil is already approved for the same age population for the prevention of cervical, vulvar and associated precancerous lesions caused by HPV types 6, 11, 16 and 18 for women. It ‘also approved for the prevention caused by types 6 and 11 in both males and females cr gain paxil weight.

‘With the early completion of enrollment in this trial and the first part of our study of vaccines in Mexico announced previously, we are on track to present the results of our two most advanced clinical programs in the first quarter of next year,’ said Rahul Dr. Singhvi, President and CEO of Novavax zoloft kava kava. ‘If the results of the study of the vaccine against seasonal flu are positive, we can move the program in Phase III clinical trials in 2010.’

This entry was posted in treatment. Bookmark the permalink.

Comments are closed.